BRD4 and hematologic disorder: However, in contrast to hematologic malignancies in which the BRD4 inhibitor-mediated downregulation of MYC correlates well with reduced cell proliferation, in solid tumors, the reduction of MYC expression and cell growth is less striking after single drug treatment (Delmore et al., 2011; Tan et al., 2018), suggesting the necessity for more effective compounds.